Can metformin prolong pregnancy in preterm pre-eclampsia? Study protocol for a Nordic multicentre randomised placebo-controlled trial (PI4)
Résumé
Introduction Pre-eclampsia affects 2–8% of all pregnancies and remains a leading cause of maternal and perinatal morbidity and mortality. A randomised trial in South Africa suggested metformin used to treat preterm pre-eclampsia (26–32 weeks’ gestation) may prolong pregnancy by 7 days compared with standard care. However, this finding was borderline significant and requires validation in higher-resource settings and in diverse populations. Here, we present a Nordic multicentre trial protocol designed to evaluate whether extended-release metformin can prolong gestation in women with preterm pre-eclampsia. Methods and analysis Pre-eclampsia Intervention 4 trial is a phase III, double-blind, multicentre randomised controlled trial conducted in Sweden, Norway and Finland aiming to investigate whether metformin can prolong gestation in preterm pre-eclampsia. A total of 294 women between 22+0 and 33+6 weeks of gestation with pre-eclampsia and planned to undergo expectant management will be enrolled. Participants are randomised to receive one gram of extended-release metformin or matching placebo three times daily. The primary outcome is prolongation of gestation defined as time from randomisation to birth. Secondary outcomes include length of neonatal hospital stay and neonatal birth weight. Adverse events will be reported in line with current clinical trial guidelines. All efficacy analyses will be conducted according to the intention-to-treat principle. Ethics and dissemination The trial is conducted in accordance with Good Clinical Practice, as defined by the International Council for Harmonisation. The protocol, including amendments, was approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency in accordance with national legislation, and authorised for Finland and Norway through the Clinical Trials Information System in accordance with the EU Clinical Trials Regulation. Results will be disseminated at international conferences and published in peer-reviewed journals and communicated via popular science outlets, media, patient organisations and the trial website: https://www.preeclampsiaresearch.com/pi-trials. Trial registration number NCT06033131.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 19/10/2026. Le document reste hébergé par sa source.
Voir le document à la source →